Please login to the form below

Not currently logged in
Email:
Password:

Circassia

This page shows the latest Circassia news and features for those working in and with pharma, biotech and healthcare.

Circassia seeks shift to AIM after failing LSE criteria

Circassia seeks shift to AIM after failing LSE criteria

and in a ‘business as usual’ move Circassia followed news of the switch with a licensing deal to add another product to its pipeline. ... The agreement between Circassia and AZ also includes a deferred Tudorza option payment of $20m payable upon

Latest news

  • Circassia exits allergy R&D after placebo effect strikes again Circassia exits allergy R&D after placebo effect strikes again

    Abandons phase IIb trial of house dust mite allergy candidate. UK biopharma company Circassia has conceded defeat in its attempt to bring a range of allergy immunotherapies to market, halting all ... That deal was valued at up to $230m, with Circassia

  • Circassia slumps as cat allergy vaccine fails late-stage trial Circassia slumps as cat allergy vaccine fails late-stage trial

    UK biotech Circassia Pharma has suffered a major blow as its lead cat allergy treatment Cat-SPIRE failed to show a benefit over placebo in a phase III trial. ... While it analyses the data to try to understand the high placebo effect, Circassia has

  • Allergy specialist Circassia buys asthma firms Allergy specialist Circassia buys asthma firms

    Circassia will pay £139m ($219m) for Aerocrine and up to £100m for Prosonix. ... Meanwhile, Prosonix provides a portfolio of products targeting asthma and other respiratory diseases that complement Circassia's existing pipeline.

  • The M&A trend in pharma The M&A trend in pharma

    Pet allergy (and biotech) company Circassia's £200m IPO has so far represented the largest of these deals in the life sciences sector this year.

  • Lilly invests in UK life sciences via biotech fund Lilly invests in UK life sciences via biotech fund

    This year has already seen allergy specialist Circassia raise £200m in an initial public offering (IPO) after years in which a small biotech companies had to partner with a larger company

More from news
Approximately 3 fully matching, plus 5 partially matching documents found.

Latest Intelligence

  • Asthma: beyond the blue and the brown Asthma: beyond the blue and the brown

    One of Imperial College’s research ventures has culminated in the development of Circassia Pharmaceuticals, a spin-out biotech whose co-founders were at the time testing a prototype vaccine technology ... This year, Circassia established a commercial

  • Deal Watch March 2017 Deal Watch March 2017

    If Circassia sublicenses the rights to Tudorza in the US, it will pay a further $80m. ... 250. AstraZeneca. Circassia Pharmaceuticals. Strategic collaboration. Tudorza (marketed) and Duaklir (phase III) in COPD.

  • Pharma deals in May 2015 Pharma deals in May 2015

    155. Prosonix/Circassia. Corporate acquisition. Portfolio of generic respiratory products includingfluticasone. 152.

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Latest appointments

More from appointments
Approximately 1 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Nobull Communications

Switched on Creative Communications. With an encyclopedic working knowledge of pharmaceutical industry rules and regulations, we create dynamic, intuitive and...

Latest intelligence

Using human insights to push healthcare communications forward
This blog highlights the value of human perspectives, showing how insights can propel healthcare communications forward to ultimately improve lives...
RWE Blog 4: The place of real-world evidence in the market access strategy
The fourth and final blog in our latest series focuses on market access strategy. This follows our evaluation of the role of real-world data (RWD) and real-world evidence (RWE) in...
RWE Blog 3: Is real-world evidence the holy grail
We began our four-blog series by evaluating the role of real-world data (RWD) and real-world-evidence (RWE) in Real-world challenges and real-world data, and understanding the payer's perspective, in Payers use...

Infographics